NYSE: EVMN/Biotechnology
Evommune, Inc.
Palo Alto, CA, United States
Company overview
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is headquartered in Palo Alto, California.
This profile is for informational purposes only and is not investment advice. Company information may change after the verification date.